搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
生物谷
5 天
柳叶刀:世界首例!iPSC干细胞治疗恢复人类视力
对于单眼LSCD患者,应首先考虑自体移植手术,因为这种移植通常能产生更好的长期移植物存活率。对于双眼LSCD患者,则无法获得自体眼部组织,因此可以考虑的手术包括捐献角膜缘干细胞移植、同种异体培养角膜上皮细胞移植以及自体培养口腔黏膜上皮细胞片移植。
6 天
on MSN
Markers in iPSC quality control—a new approach to enhance standardization
Human induced pluripotent stem cells (iPSCs) have a great potential for scientific and medical applications. They are used in ...
9 天
华夏源类器官 |《Cell》子刊:合成新型胰腺癌类器官,成功模拟肿瘤 ...
本研究论文的共创作者Tanimizu Naoki博士总结道,“目前,胰腺导管腺癌的抗癌药物在临床试验阶段都以失败告终。因此,具有独特肿瘤微环境特征的胰腺癌类器官的出现,应用于抗癌药物的筛选。 增殖性胰腺癌肿瘤类器官呈现出的耐药性及增殖潜能, ...
腾讯网
8 天
Cell子刊:井然等人揭示增强iPSC-CAR-T细胞抗肿瘤效果新方法
撰文丨王聪编辑丨王多鱼排版丨水成文嵌合抗原受体T细胞疗法(CAR-T细胞疗法)的出现,是近年来癌症免疫治疗领域的一大突破,自2017年以来,美国FDA已经批准了6款CAR-T细胞疗法上市,用于治疗白血病、淋巴瘤等血液类癌症,展现了让人印象深刻的强大效 ...
studyfinds on MSN
2 天
Breakthrough stem cell surgery restores vision among several human patients
In a remarkable medical breakthrough, doctors have successfully used stem cells to treat a debilitating eye condition that ...
2 天
on MSN
World’s first stem-cell treatment restores vision for patients with severe corneal damage
Japanese scientists conducted a clinical trial using stem cells to treat severe corneal damage. The trial involved four ...
3 天
World First: Stem Cell Transplant Restores Sight In Multiple Patients
Two years after surgery, three patients experienced improved corneal transparency with no serious side effects.
News Medical on MSN
2 天
Largest ALS patient-based iPSC repository opens new frontiers in research
In a landmark continuing collaboration, Answer ALS and Cedars-Sinai have announced the completed availability of the largest ...
Macau Business
5 天
Cutting-Edge Stem Cell Technology Captures the Heart of Asian King – iPSC Family Stem ...
This advanced biotechnology offers a level of protection that is truly unparalleled.” Supported by the Taiwan government’s ...
Taiwan News
9 天
Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted ...
Off-the-shelf Product Candidate Incorporates Novel Sword & Shield Technology Designed to Promote Functional Persistence without Conditioning Chemotherapy FT836 Preclinical Data Shows Robust ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈